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ABSTRACT
The efﬁcacy and safety of a combination regimen
including either efavirenz or lopinavir–ritonavir
was examined in a cohort of 65 patients positive for
human immunodeﬁciency virus-1 (HIV-1). Both
the efavirenz (n = 33, 18 anti-retroviral naive) and
lopinavir–ritonavir (n = 32, 15 naive) regimens
achieved signiﬁcant changes from baseline CD4
cell counts and HIV RNA levels after 108 weeks
(p < 0.01). Despite diminished immunological and
virological parameters at study entry, the lopina-
vir–ritonavir group showed greater virological
effects than the efavirenz group after 108 weeks
(median change 3.3 log10, interquartile range
(IQR) 2.2–3.8 log10 vs. 2.4 log10, IQR 0.9–3.3 log10,
respectively, p 0.004). Use of lopinavir–ritonavir,
in contrast to use of efavirenz, was associated with
signiﬁcant hypertriglyceridaemia.
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Recent guidelines concerning the initiation of
therapy against human immunodeﬁciency virus-
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1 (HIV-1) infection emphasise long-term effective-
ness, safety and tolerability of the anti-retroviral
regimen [1,2]. Both efavirenz, a non-nucleoside
reverse transcriptase inhibitor [3], and lopinavir–
ritonavir, a protease inhibitor [4], are recommen-
ded ﬁrst-line drugs [1,5]. Head-to-head studies
evaluating the long-term efﬁcacy and safety of
regimens including efavirenz or lopinavir–ritona-
vir are rare [6,7]. This study describes such an
assessment, which took place within a 108-week
retrospective cohort study.
HIV-infected individuals (n = 65; 86% males;
median age 40 years) received either efavirenz
(group A; n = 33) or lopinavir–ritonavir (group B;
n = 32) as part of a combination anti-retroviral
regimen with two nucleoside reverse transcrip-
tase inhibitors (NRTIs) for 108 weeks. All patients
were followed prospectively with regular clinical
and laboratory evaluation, including fasting lipid
measurements, CD4 T-cell counts (cells ⁄mm3) by
ﬂow cytometry, and HIV RNA levels (copies ⁄mL
by the branched-chain DNA signal ampliﬁcation
method). Any adverse events, e.g., lipodystrophy,
were recorded. Lipid-lowering therapy was insti-
tuted if necessary according to published guide-
lines [8].
Values are expressed as median and interquar-
tile range. Comparisons within each group were
made cross-sectionally for values at baseline and
after 108 weeks. Independent-sample t-tests were
used to compare normally distributed continuous
variables between groups. TheWilcoxon rank sum
and Mann–Whitney tests were used to compare
non-parametric data within and between groups.
All testswere two-tailed.Datawere analysedusing
SPSS v. 10.0 software (SPSS Inc., Chicago, IL,USA).
The most common NRTI combination used
was stavudine (d4T) + lamivudine (3TC) (40%)
(Table 1), and only one NRTI was substituted in
60% of the anti-retroviral-experienced patients.
All patients underwent genotypic resistance test-
ing before initiation or change of treatment.
At baseline, group A and B patients differed
with respect to median CD4 counts (300 vs.
211 cells ⁄mm3, respectively; p 0.05) and HIV
RNA values (4.1 log10 vs. 5 log10, respectively;
p < 0.01). Baseline CD4 values did not differ
among anti-retroviral-experienced patients in
both groups (p 0.12), but HIV RNA values did
(2.6 log10 vs. 4.7 log10, respectively; p < 0.001).
For naive subjects, median baseline CD4 cell
counts did not differ between the two groups
(p 0.2), but median baseline HIV RNA levels were
higher in group B than in group A naive patients
(p 0.05; Table 1).
At 108 weeks, median CD4 cell counts in-
creased signiﬁcantly from baseline in both groups
(p < 0.01), but ﬁnal CD4 values did not differ
between groups (p 0.2; Table 2). The lopinavir–
ritonavir group appeared to experience a stronger
effect on CD4 increases (median of 146 (23–392)
vs. 275 (212–383) cells ⁄mm3 for efavirenz and
lopinavir–ritonavir, respectively; p 0.058).
Viral load decreased by a median of 2.4 log10
for the efavirenz group vs. 3.3 log10 for the
lopinavir–ritonavir group at 108 weeks (p < 0.01
for both groups compared with baseline values;
Table 2). The between-group comparison showed
Table 1. Baseline characteristics and nucleoside reverse transcriptase inhibitor (NRTI) regimens of the two study groups
Group A (efavirenz) Group B (lopinavir–ritonavir)
TotalNaive Experienced Naive Experienced
Age, median, years (IQR) 40 43 40 41 40 (24–73)
n (% male) 18 (72) 15 (83) 15 (94) 17 (94) 65 (86)
NRTI backbone regimen
d4T + 3TC 6 8 7 4 25
AZT + 3TC 7 3 2 1 13
ddI + 3TC 3 1 4 4 12
ddI + TDF 1 1 0 5 7
ddI + d4T 1 1 1 2 5
Other combination 0 1 1 1 3
Median CD4 count, cells ⁄mm3 (IQR) 300 (155–548)a 211 (78–417)
Median CD4 count, cells ⁄mm3 (IQR) 299 (137–453) 336 (189–698) 209 (90–307) 342 (51–461)
HIV RNA, copies ⁄mL, median (IQR) 4.1 (2.7–5)b 5 (4.2–5.7)
HIV RNA, copies ⁄mL, median (IQR) 4.9 (4.2–5.2)c 2.6 (1.7–3.3)d 5.2 (4.9–5.8) 4.7 (3.4–5.5)
ap 0.05 for comparison between group A and group B patients.
bp < 0.01 for comparison between group A and group B patients.
cp 0.05 for comparison between naive subgroup A and naive subgroup B.
dp < 0.001 for comparison between experienced subgroup A and experienced subgroup B.
IQR, interquartile range; HIV, human immunodeﬁciency virus; d4T, stavudine; AZT, zidovudine; ddI, didanosine; 3TC, lamivudine; TDF, tenofovir.
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a more pronounced effect for the lopinavir–
ritonavir group (p 0.004). With intention-to-treat
analysis, 94% of patients achieved HIV RNA
levels of < 50 copies ⁄mL. Two anti-retroviral-
experienced patients from each group discontin-
ued the study regimen at 8 weeks after baseline.
All but one patient in group A, and two in group
B, achieved undetectable viral loads by the 24th
week of follow-up (on treatment analysis). These
were experienced patients who eventually
achieved undetectable viral loads.
Lipodystrophy was documented for 23% (7 ⁄ 31;
two naive) and 33% (10 ⁄ 30; ﬁve naive) of group A
and group B patients, respectively (p 0.4). Their
NRTI backbone was mainly d4T + didanosine
(ddI) (82%). All affected individuals showed
signs of lipoatrophy and ⁄ or lipohypertrophy at
54 weeks after initiation of treatment.
At baseline, median triglyceride (TG) and total
cholesterol (CHOL) values were 148 (103–
193) mg ⁄dL and 183 (171–231) mg ⁄dL vs. 156
(122–235) mg ⁄dL and 200 (180–240) mg ⁄dL for
group A and group B patients, respectively (p not
signiﬁcant). At baseline, 12.1% (4 ⁄ 33) of group A
and 6.3% (2 ⁄ 32) of group B patients were receiv-
ing lipid-lowering therapy. At 108 weeks, TG
levels were stable at 146 (111–227) mg ⁄dL (p not
signiﬁcant), while CHOL was elevated at 227
(195–260) mg ⁄dL (p 0.002 compared to baseline)
in the efavirenz group. The lopinavir–ritonavir
group had elevations in both TG and CHOL
(median values 273 (182–383) vs. 253 (208–
281) mg ⁄dL, respectively; p 0.001 for both com-
parisons with baseline). Fasting grade 3 CHOL
(>300 mg ⁄dL) and TG (>700 mg ⁄dL) occurred in
9.2% and 18.8% of patients, respectively. A lipid-
lowering agent (mainly a ﬁbrate) was adminis-
tered during treatment to 3% (1 ⁄ 33) of group A
and 15% (5 ⁄ 32) of group B patients.
No differences between groups with regard to
adherence and compliance were found. Two
(6.1%) patients receiving efavirenz and two
(6.3%) receiving lopinavir–ritonavir interrupted
treatment because of adverse central nervous
system events and gastrointestinal symptoms,
respectively.
Both the efavirenz and the lopinavir–ritonavir
groups achieved signiﬁcant immunological and
virological improvements, as reported previously
[3,9]. The high efﬁciency observed differs from
that found in previous studies and can be attrib-
uted to: (1) the patients being either naive (51%)
or having experienced only one treatment failure
(49%); (2) the high level of compliance and
adherence, as well as the excellent performance
status of all patients studied; and (3) the fact that
genotypic resistance testing was performed before
initiation or change of treatment.
A major drawback of the present study is the
signiﬁcant differences between the two groups in
terms of both immunological and virological
parameters at baseline. This discrepancy might
have affected meaningful comparisons between
groups, and could be attributed partially to
physicians favouring the use of protease inhibi-
tors in more immunosuppressed patients. Despite
this difference, the lopinavir–ritonavir group
showed signiﬁcant increases in CD4 values and
viral load in both naive and experienced patients,
and these increases did not differ from those in
the efavirenz group. Thus, immune recovery and
virological efﬁcacy may be better with lopinavir–
ritonavir combinations, as suggested by two
studies examining only anti-retroviral naive
Table 2. Baseline and ﬁnal CD4 cell counts and human immunodeﬁciency virus RNA values according to treatment group
and anti-retroviral naive vs. experienced status. Change from baseline values and comparison between baseline and ﬁnal
values is shown together with corresponding p values. Values are presented as median and interquartile range. Viral load
is expressed in log10 values
Total Anti-retroviral naive Anti-retroviral experienced
Week 0 Week 108
Changes
from
baseline p Week 0 Week 108
Changes
from
baseline p Week 0 Week 108
Changes
from
baseline p
Group A
EFV
CD4 300 (155–548) 495 (320–760) 146 (23–392) <0.01 290 (317–453) 534 (315–760) 347 (95–435) 0.02 336 (189–698) 468 (320–682) 82 () 50–149) 0.3
Viral
load
4.1 (2.7–5) 1.7 (1.7–1.7) 2.4 (0.9–3.3) <0.01 4.9 (4.2–5.2) 1.7 (1.7–1.7) 3.2 (2.5–3.5) <0.01 2.6 (1.7–3.3) 1.7 (1.7–1.7) 0.7 (0–1.3) 0.02
Group B
LOP ⁄RIT
CD4 211 (78–417) 420 (352–756) 275 (212–383) <0.01 209 (90–307) 500 (369–763) 296 (253–453) <0.01 342 (51–461) 392 (303–683) 237 (61–343) <0.01
Viral
load
5 (4.2–5.7) 1.7 (1.7–1.7) 3.3 (2.2–3.8) <0.01 5.2 (4.9–5.8) 1.7 (1.7–1.7) 3.5 (3.2–4.1) <0.01 4.7 (3.4–5.5) 1.7 (1.7–1.7) 2.7 (1.6–3.4) <0.01
EFV, efavirenz; LOP ⁄RIT, lopinavir–ritonavir.
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subjects [6,7]. This observation is strengthened by
the fact that the tenofovir (TDF) + ddI backbone,
known to affect immune recovery adversely, was
used more frequently in the lopinavir–ritonavir
group (Table 1) [10].
Patients in both arms of the study developed
lipodystrophy, possibly associated with the use
and duration of anti-retroviral therapy [11,12].
Long-term exposure to NRTIs, especially d4T,
probably contributed to this effect [13,14]. The
lopinavir–ritonavir group displayed both hyper-
cholesterolaemia and hypertriglyceridaemia,
whereas the efavirenz group showed hyperchole-
sterolaemia only, as shown previously [15,16]. A
previous study also found a diminished lipid
effect with lopinavir–ritonavir, but examined both
CHOL and TG elevations under conditions of
dyslipidaemia [6].
In addition to the immunological differences at
baseline, the study was limited by its retrospective
nature, the low numbers of patients and the poor
homogeneity of the backbone regimens. Neverthe-
less, both regimens performed well with respect to
their immunological and virological effects.
Although the superiority of one arm cannot be
excluded, since the lopinavir–ritonavir group had
diminished immunological and virological para-
meters at study entry, the lopinavir–ritonavir
combination appeared to confer enhanced thera-
peutic effects compared with efavirenz. Hypertri-
glyceridaemia was observed more commonly in
the lopinavir–ritonavir group. Future prospective
trials comparing patients with similar immunolo-
gical status at study entry are necessary in order to
further elucidate the role of each drug in providing
an adequate and safe anti-retroviral effect.
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